93,962 Shares in Amgen Inc. $AMGN Purchased by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 93,962 shares of the medical research company’s stock, valued at approximately $26,516,000.

Several other institutional investors have also modified their holdings of AMGN. Evelyn Partners Investment Management LLP acquired a new position in Amgen during the second quarter worth $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen in the second quarter valued at $32,000. Cloud Capital Management LLC purchased a new position in shares of Amgen in the third quarter valued at $34,000. AXS Investments LLC acquired a new position in shares of Amgen during the 3rd quarter worth $42,000. Finally, Winnow Wealth LLC acquired a new position in shares of Amgen during the 3rd quarter worth $47,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 2.7%

AMGN stock opened at $351.48 on Thursday. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The stock has a market capitalization of $189.47 billion, a P/E ratio of 24.70, a PEG ratio of 3.58 and a beta of 0.45. The company has a 50 day moving average price of $359.46 and a two-hundred day moving average price of $326.94. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMGN. Barclays initiated coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. The Goldman Sachs Group increased their price target on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Morgan Stanley increased their target price on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Finally, Cantor Fitzgerald boosted their price target on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $354.00.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.